Suppl. Fig. S5


A
Enrollment
Assessed for eligibility (n= 3067)
Excluded (n= 2894)
Not age, gender, race, liver disease etiology matched Controls and also not on the 2:1 basis (n= 2894)
Randomized (n= 173)
Serum samples (n= 369)
Allocation
Allocated HCC cases (n= 44)
Received serum samples allocated VirScan (n= 134)
Did not receive allocated VirScan (n= 0)
Allocated Controls cases (n= 129)
Received serum samples allocated VirScan (n= 235)
Did not receive allocated VirScan (n= 0)
Follow-up
Follow-up at baseline (n= 40)
Follow-up at 12-month pre-HCC (n= 26)
Follow-up at 6-month pre-HCC (n= 24)
Follow-up at diagnosis (n= 44)
Follow-up at baseline (n= 129)
Follow-up at diagnosis (n= 106)
QC
Pass the QC (n= 44)
Excluded from analysis (reads quality less than 10, 000 or not HCC cases) (n= 0)
Pass the QC (n= 129)
Excluded from analysis (reads quality less than 10, 000 or not HCC cases) (n= 0)
Analysis
Analysed (n= 44)
Excluded from analysis (n= 0)
Analysed (n= 129)
Excluded from analysis (n= 0)
B
p=0.21 (Below vs High)
P-trend=0.18
Overall Survival (%)
below
low
High
Months
C
Sensitivity
Specificity
- 10 yrs
- 9 yrs
- 8 yrs
- 7 yrs
- 6 yrs
- 5 yrs
- 4 yrs
- 3 yrs
- 2 yrs
- 1 yr
D
NIDDK (Diagnosis)
NAFLD
Diabetes
Creatinine
Hep B
Hep C
ALT
Prothromb T
Bilirubin Tot
Albumin
AFP
PLT
Cirrhosis
All Clinical
AUC (95% CI)
E
NCI-UMD
NASH
Hep C
Diabetes
Hep B
PLT
Creatinine
ALT
Bilirubin Tot
Cirrhosis
Albumin
AFP
Prothromb T
All Clinical
AUC (95% CI)